您现在的位置: 首页> 研究主题> 肝/病理学

肝/病理学

肝/病理学的相关文献在1996年到2020年内共计161篇,主要集中在内科学、中国医学、药学 等领域,其中期刊论文161篇、专利文献12425篇;相关期刊41种,包括吉林中医药、中国中医药科技、中华实验和临床病毒学杂志等; 肝/病理学的相关文献由684位作者贡献,包括许建明、毛远丽、赵景民等。

肝/病理学—发文量

期刊论文>

论文:161 占比:1.28%

专利文献>

论文:12425 占比:98.72%

总计:12586篇

肝/病理学—发文趋势图

肝/病理学

-研究学者

  • 许建明
  • 毛远丽
  • 赵景民
  • 辛绍杰
  • 庞栋
  • 张玲霞
  • 盛国光
  • 陈菊梅
  • 丁长海
  • 周大桥
  • 期刊论文
  • 专利文献

搜索

排序:

年份

    • 王蔚; 赵伟; 肖丽; 咸建春; 尹有美
    • 摘要: 目的 评估慢性乙型肝炎病毒(HBV)感染者显著肝脏组织学改变的相关因子预测效果.方法 选取2012年10月至2015年12月江苏省泰州市人民医院收治的慢性乙型肝炎初治并接受肝活检术患者157例,回顾性分析其肝组织学和生化检查相关资料.结果 清蛋白(ALB)水平与肝组织学炎症水平显著相关(r=-0.236,P=0.003).ALB、球蛋白(GOLB)、年龄、血小板计数(Plt)、凝血酶原时间(PT)、谷草转氨酶(AST)是显著肝纤维化的独立预测因子(r=-0.291、0.249、0.245、-0.383、0.256、0.235,P=0.001、0.002、0.002、0.001、0.001、0.003).在谷丙转氨酶(ALT)正常的慢性HBV感染者中,AST、白细胞(WBC)、HBV DNA定量与重度肝纤维化显著相关(r=0.370、0.304、0.287,P=0.001、0.041、0.012);而在ALT异常患者中,年龄、ALB、GOLB、Plt、PT与重度肝纤维化显著相关(r=0.290、0.273、0.317、0.422、0.413,P=0.003、0.001、0.004、0.001、0.002);在HBV e抗原(HBeAg)阳性患者中,年龄、AST、谷氨酰转肽酶、Plt、PT与肝纤维化显著相关(r=0.295、0.206、0.373、0.475、0.401,P=0.010、0.016、0.027、0.016、0.009);在HBeAg阴性患者中,ALB、GOLB、WBC、Plt、PT与肝纤维化显著相关(r=0.314、0.207、0.288、0.531、0.320,P=0.001、0.004、0.005、0.001、0.035).Plt是预测肝纤维化的优秀因子(P=0.001,受试者工作特征曲线下面积为0.805).结论 Plt在慢性HBV感染者中是一个较好的肝纤维化预测指标.
    • 刘欣欣; 王耀顷; 王上; 郭明杰; 刘林; 张赤志
    • 摘要: Objective To investigate the protective effect of Shenxi Dan,a recipe for cooling blood,activating blood and inducing resuscitation,on multiple organ damage of rats with endotoxic shock.Methods The SD rats were randomly divided into normal group,model group and Shenxi Dan group.Except for the normal group,the rats in the other groups were given intraperitoneal injection of D-galactosamine (GalN) and intravenous injection of lipopolysaccharide (LPS) to induce endotoxic shock.The changes in mean arterial pressure (MAP) during the entire process were monitored.Serum samples and liver and lung tissues were collected after infusion for 0 h,2 h,6 h,respectively,and then the amount of whole blood cells,serum contents of total bilirubin (TB),lactate dehydrogenase (LDH),aspartate aminotransferase (AST),and alanine aminotransferase (ALT) were detected.Meanwhile,the pathological changes in lung and liver tissues after hematoxylin-eosin (HE) staining were observed under light microscope.Results Compared with the model group,the decrease degree of the blood pressure was mild,platelet count(plt) was not decreased obviously,while the increase of serum TB,LDH,AST,ALT contents was significantly inferior,and inflammatory pathological changes of lung and liver tissues significantly were much relieved in Shenxi Dan group.Conclusion Shenxi Dan can improve lung and liver function of endotoxic shock rats,reduce the pathological damage,and improve microcirculation,which is helpful to clinical treatment of endotoxic shock.%[目的]观察凉血活血开窍方神犀丹对内毒素休克大鼠多脏器功能损伤的保护作用.[方法]将SD大鼠随机分为正常组、模型组和神犀丹组,除正常组外,其他2组大鼠腹腔注射D-氨基半乳糖(GalN)和尾静脉注射脂多糖(LPS)复制内毒素休克模型,全程监测平均动脉压(MAP)的变化,分别在输注0、2、6h时采集血清标本及肺肝组织,检测全血细胞、血清总胆红素(TB)、乳酸脱氢酶(LDH)、谷草转氨酶(AST)、谷丙转氨酶(ALT)的含量,苏木素—伊红(HE)染色后光镜下观察大鼠肺肝组织的病理学改变.[结果]神犀丹组血压下降程度较模型组轻,血小板计数(PLT)无明显降低,血清TB、LDH、AST、ALT的含量上升幅度显著低于模型组,神犀丹组肺肝组织炎性病理改变较模型组明显减轻.[结论]神犀丹能改善内毒素休克大鼠的肺肝功能,减轻病理损害,改善微循环.
    • 范宸颖; 覃小梅; 彭慧云; 李双杰
    • 摘要: 【目的】探讨儿童慢性乙型病毒性肝炎的肝脏病理变化与肝功能、肝纤维化血清学指标、血清乙肝病毒的脱氧核糖核酸(HBV-DNA)载量的相关性。【方法】回顾性分析2010年7月至2015年6月本院肝病中心收治确诊的79例慢性乙型病毒性肝炎临床病理资料。收集患儿的术前3 d的肝功能、肝纤维化血清学四项指标、HBV-DNA病毒载量等检测指标。根据肝脏病理改变程度分为轻度和中重度炎症损伤两组及无肝纤维化和肝纤维化两组,分析与其血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、总蛋白(Abl)、Ⅲ型胶原蛋白(PCⅢ)、层粘连蛋白(LN)、透明质酸酶(HA)、Ⅳ型胶原蛋白(Ⅳc)水平及 HBV-DNA载量的关系。【结果】轻度肝脏炎症组57例,中重度肝脏炎症组22例,两组的ALT、AST、Abl及 HBV-DNA载量的差异比较均无统计学意义(P >0.05)。无肝脏纤维化组19例,肝脏纤维化组60例,两组的肝纤维四项指标发现Ⅲ型胶原蛋白、层粘连蛋白、透明质酸酶及 IV型胶原蛋白差异比较具有统计学意义(P 0.05)。【结论】肝功能及 HBV-DNA载量不能预测儿童慢性乙型病毒性肝炎的肝脏病理炎症改变程度,肝纤维四项对评估患儿肝脏纤维化程度有一定临床意义。肝穿刺活检为评估患儿肝脏病理改变的金标准,对于指导儿童乙型病毒性肝炎的治疗具有重要作用。%obj ective]To investigate the correlation between liver pathological changes and liver function,ser-um markers of liver fibrosis and serum HBV DNA (HBV-DNA)in children with chronic hepatitis B (CHB).[Methods]Clinical and pathological data of 79 patients with chronic hepatitis B in our hospital from July 2010 to June 2015 were analyzed retrospectively.The liver function,liver fibrosis serological four indicators,HBV-DNA viral load and other detection indicators of the children 3d before surgery were collected.According to the degree of liver pathological changes,they were divided into two groups,the mild group and the moderate/severe inflamma-tion group,and other two groups as the no liver fibrosis group and liver fibrosis group.Analysis of serum glutamic pyruvic transaminase (ALT),aspartate aminotransferase (AST),total protein (ABL)and type Ⅲ (PCⅢ),lami-nin (LN),hyaluronic acid enzyme (HA),type Ⅳ collagen (Ⅳ C)and the levels of HBV-DNA load were conduc-ted accordingly.[Results]With 57 cases in mild liver inflammation group and 22 cases in moderate/severe liver inflammation group,there were no significant differences in the ALT,AST,Abl and HBV-DNA loads in the two groups (P >0.05).Within 19 cases of no liver fibrosis group and 60 cases of liver fibrosis group,compared statis-tical differences were found in type Ⅲ collagen,laminin,hyaluronic acid enzyme and type Ⅳ collagen in the liver fiber four indexes of the two groups (P 0.05).[Con-clusion]Liver function and HBV-DNA load can not predict the degree of liver pathological changes in children with chronic hepatitis B,liver fiber four indexes are able to assess the degree of liver fibrosis in patients with a certain degree of clinical significance.Liver biopsy is the gold standard for evaluating the pathological changes of liver in children,which has an important role in guiding the treatment of children with hepatitis B.
    • 丁美云; 高婷; 卫园园; 赵丽; 詹江华
    • 摘要: 目的:研究转化生长因子-β1(Transforming growth factor—β1,TGF —β1)、促纤维化通路中TGF—β1、P—Smad3等通路蛋白在胆道闭锁(Biliary atresia,BA)肝纤维化进程中的作用机制。方法选取2010年1月到2015年7月我们收治的胆管扩张症肝活检病例10例,为胆扩组;BA 肝活检病例19例,为 Kasai 组;BA 晚期肝移植患者自体肝活检病例11例,为移植组11例。进行苏木素/伊红(HE)、马松(Masson)染色观察肝标本纤维化评价其纤维化程度,免疫组化(Immunohistochemistry,IHC)染色检测TGF—β1、Smad2—4、P—Smad2—3及人纤溶酶原激活物抑制因子1(PAI—1)在肝组织中的表达,结合 BA 肝纤维化病理分级标准探讨 TGF —β1等通路蛋白在肝纤维化进程中的作用。结果HE 及 Masson:胆扩组偶见纤维细胞增生,Kasai 组胶原纤维增生、桥接纤维化现象显著,移植组假小叶显著。免疫组化:①定性分析:胆扩组肝内 Smad 2、Smad 4、PAI —1为阳性表达,其余为弱阳性;Kasai 组 TGF —β1等蛋白均在肝细胞胞质阳性表达,P—Smad 2、P—Smad 3、Smad 4在胞核亦呈阳性表达;移植组患儿肝内 TGF—β1等蛋白皆为弱阳性表达。②半定量分析:三组中 Kasai 组 TGF —β1、Smad 3、P—Smad 3及 PAI —1含量表达明显高于其他两组(P <0.05),随着 TGF —β1、Smad3、P— Smad3及 PAI —1逐渐升高肝纤维化逐渐加重;P —Smad3与 PAI —1含量大小及变化幅度密切相关,促肝纤维化作用显著;Smad2、P — Smad2、Smad4组间无差异,在通路中连接相关蛋白。移植组 TGF —β1等通路蛋白含量均少于 Kasai 组,随着肝硬化加重而逐渐减少。结论BA 肝内 TGF —β1促纤维化通路中 TGF —β1、Smad3显著促进肝纤维化,P — Smad3与肝纤维化进程密切相关。%Objetive To observe the function of TGF—β1 and P—Smad3 etc in TGF—β1 signal pathways in liver fibrosis of biliary atresia.Methods Liver biopsy specimens were collected from congenital biliary dila-tation (CBD group,n =10),biliary atresia patients who had Kasai procedure (Early hepatic fibrosis group,n =19),liver transplantation(transplantation group,n =11),the first two groups were collected from Jan.2010 to Jul.2015 in Tianjin childrens′hospital,the last group was collected from Jan.2013 to Jan.2014 in Tianjin first central hospital.The hematoxylin &eosin staining were used to observe the degree of liver fibrosis of every sin-gle sample,immunohistochemistry were used to observe the expression of TGF — β1、Smad 2 —4、P — Smad 2 ~3 and PAI—1 in liver tissues of these samples.Results HE and Masson:the CBD group had mild fiber cells hy-perplasia,the Kasai group had Proliferation of collagen fibers and bridging fibrosis phenomenon,the transplanta-tion group had significant pseudolobule.Immunohistochemistry:①qualitative analysis:in the CBD group,Smad 2,Smad 4,PAI — 1 expression is positive,the rest is weakly positive;in the Kasai group,the all proteins in the TGF —β1 signal pathways expressed in the liver cytoplasm,P— Smad 2,P — Smad 3,Smad 4 expression was also found in the nucleus;in the liver transplantation group,the expression of all proteins in the TGF — β1 signal pathways were weakly positive.②semi-quantitative analysis;The level of TGF—β1、Smad 3、P—Smad 3 and PAI— 1 in the Kasai group have a significant rise than the other groups(P 0.05).All of the proteins in the TGF —β1 signal pathways were decreased in transplantation group (P <0.05). Conclusions TGF—β1 and Smad 3 made a contribution to liver fibrosis in the early stage of bili-ary atresia,and P—Smad 3 is closely related with the progress of liver fibrosis.
    • 朱明慧; 李阳阳; 赵艳丽; 赵海潞; 刘承伟
    • 摘要: [目的]探讨小鼠和食蟹猴帕金森病(PD)模型中肝脏变化.[方法]选用雄性C57BL小鼠20只,16月龄,随机分为正常组和造模组,每组10只,造模组采用腹腔注射1-甲基-4-苯基l,2,3,6-四氢吡啶(MPTP,剂量为25 mg/kg)5周.雄性食蟹猴8只,10岁左右,随机分为正常组3只及造模组5只,造模组以MPTP静脉注射30 d(剂量为0.2 mg·kg-1·d-1).动物造模过程中观察行为学并记录.食蟹猴造模成功后,抽血测量肝功能.动物麻醉安乐死后,取肝脏,进行苏木精—伊红(HE)、糖原(PAS)染色,并观察病理学改变.[结果]PD小鼠模型和食蟹猴模型成功建立,食蟹猴肝功能检测结果显示:造模组总蛋白和白蛋白含量均显著降低(P<0.05).PD小鼠肝索细胞排列紊乱,肝窦扩张,肝细胞变性坏死,糖原减少.PD食蟹猴肝细胞排列相对紊乱,肝窦明显扩张,糖原明显减少.肝细胞发生变性、坏死,肝细胞核深染,肝细胞间充满粉红色的、粗细不等的颗粒状物,有程度不等的炎性细胞浸润.[结论]帕金森病的发病可能与肝脏功能和结构改变相关.
    • 周志愉; 余功; 饶斌; 谢斌
    • 摘要: [目的]观察破血逐瘀中药虻虫对荷H22小鼠肝癌组织血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)蛋白表达的影响.[方法]选用雄性昆明种(KM)小鼠50只随机分为模型组,化疗组,虻虫高、中、低剂量组.腋下注射H22细胞建立荷H22肝癌小鼠模型.虻虫治疗组以0.045、0.09、0.18 g·kg-1·d-1剂量灌胃给药,化疗组以5-氟尿嘧啶(5-FU)25 mg·kg-1· d-1剂量腹腔注射给药,隔日1次;模型组予以等容积生理盐水灌胃给药,2周后处死小鼠,称体质量及瘤体质量,采用苏木精—伊红(HE)染色观察肝癌组织形态变化,免疫组织化学法检测VEGF及MMP-9蛋白的表达.[结果]高、中剂量虻虫组均可使肝癌组织呈大片坏死;虻虫高、中剂量组及化疗组瘤体质量、瘤指数显著减小,虻虫高剂量组VEGF及MMP-9蛋白表达显著减小,与模型组比较,差异均有统计学意义(P<0.01).[结论]破血逐瘀中药虻虫能显著抑制荷H22小鼠肝癌细胞增殖,其机理可能与减少VEGF、MMP-9蛋白表达有关.
    • 黄玉影; 李常青; 陈斯泰; 黄志刚; 郭洁文; 李小翚; 屈喜玲
    • 摘要: [目的]观察荔枝核有效部位群(SLEC)对大鼠非酒精性脂肪肝(NAFLD)的治疗作用,并探讨其作用机制.[方法]选用SPF级大鼠,雌雄各半,采用高脂饲料加高脂乳液灌胃8周复制NAFLD模型,造模成功后将造模组大鼠根据体质量和血糖值随机分为模型组、SLEC低剂量组(剂量为0.74 g·kg-1·d-1)、SLEC高剂量组(剂量为1.48 g·kg-1·d-1)和二甲双胍组(剂量为100 mg·kg-1·d-1),每组8只,雌雄各半,并设正常组为对照.给药4周后,腹主动脉采血、取肝组织.采用全自动生化分析仪检测血清甘油三酯(TG)、胆固醇(CHOL)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、空腹血糖(FBG);采用比色法检测血清游离脂肪酸(NEFA)、放射免疫法检测血清胰岛素(Ins)含量,计算稳态模型胰岛素抵抗指数(HOMA-IR)、胰岛素敏感性指数(ISI);采用甘油磷酸氧化酶—过氧化物酶偶联(GPO-PAP)法、胆固醇氧化酶—过氧化物酶偶联(COD-PAP)法、水溶性四氮唑(WST-1)法、硫代巴比妥酸(TBA)法分别检测肝组织TG、CHOL、超氧化物歧化酶(SOD)和丙二醛(MDA)含量;观察大鼠肝脏组织病理变化,采用实时荧光定量PCR和Western-blot法分别检测大鼠肝组织固醇调节元件结合蛋白-1c(SREBP-1c)mRNA和蛋白的表达.[结果]SLEC高剂量组能显著降低NAFLD大鼠血清TG、LDL-C、NEFA和肝脂质含量,提高大鼠血清SOD含量,明显改善大鼠HOMA-IR、提高ISI,与模型组比较差异均有统计学意义(P<0.05),且SLEC高剂量组改善肝细胞脂质沉积作用明显.与模型组比较,SLEC高、低剂量均能显著降低大鼠肝组织SREBP-1c mRNA及蛋白表达(P<0.05).[结论]SLEC对NAFLD大鼠肝细胞脂质沉积的病理状况具有明显改善作用,作用机制与调节脂质代谢、降低NEFA水平,改善IR、抗氧化应激和下调SREBP-1c基因与蛋白表达有关.
    • 陈书远; 陈国华; 魏苗苗; 丁凤; 张旸
    • 摘要: Objective] To explore the effects of deferoxamine (DFO) on cardiohepatic iron deposition sta‐tus and glucose metabolism in children with severe β‐thalassemia .[Methods] From September 2012 to October 2013 at our hospital ,60 children of severe β‐thalassemia were recruited for evaluations of serum ferritin (SF) , sugar metabolism and cardiohepatic iron deposition (MRIT2 * value) .And re‐examinations were performed after a 12‐month treatment of DFO .[Results] Normal index rate of hepatic iron deposition increased to 10 .0%from 36 .7% and cardiac iron deposition rose to 20 .0% from 48 .3% .And the differences were statistically significant before and after treatment ( P 0 .05) .However , blood glucose 2h after oral glucose (PG2h) and insulin (FINS2h) decreased markedly .And the differences were statistically significant ( P < 0 .05) .[Conclusion] Deferoxamine can effectively reduce cardiohepatic iron deposition and improve glucose metabolism in children with severe β‐thalassemia .%【目的】观察分析去铁胺(DFO)对重型β地中海贫血患儿心脏及肝脏铁沉积状态以及糖代谢的影响。【方法】选择2012年9月至2013年10月来本院治疗的60例β地中海贫血患儿,对患儿的血清铁蛋白(SF)、糖代谢水平、心脏及肝脏的铁沉积状况(MRI T2倡值)进行分析,评估 DFO 治疗12个月后患儿的健康情况。【结果】DFO 治疗12个月后β地中海贫血患儿的心脏、肝脏铁沉积状况均得到相应改善:肝铁沉积程度正常指标率从10.0%增加到了36.7%,心铁沉积程度正常指标率从20.0%增加到了48.3%,治疗前后差异具有明显统计学意义( P < 0.05);治疗后 SF 也显著下降,与治疗前相比较,差异具有统计学意义( P <0.05);患儿治疗后空腹血糖(FPG)、空腹胰岛素(FINS)与治疗前比较,差异无显著性( P > 0.05)但餐后2 h血糖(2hPG)、胰岛素(2hFINS)明显降低,差异有统计学意义( P < 0.05)。【结论】DFO 可以有效降低重型β地中海贫血患儿心脏及肝脏铁沉积状态以及改善糖代谢,值得在临床上推广应用。
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号